Journal of Thoracic Oncology, 16(5), 860-867. International Association for the Study of Lung Cancer Faivre-Finn, C, Vicente, D, Kurata, T, Planchard, D, Paz-Ares, L, Vansteenkiste, J F, Spigel, D R, Garassino, M C, Reck, M, Senan, S, Naidoo, J, Rimner, A, Wu, Y-L, Gray, J E, Özgüroğlu, M, Lee, K H, Cho, B C, Kato, T, de Wit, M, Newton, M, Wang, L, Thiyagarajah, P & Antonia, S J 2021, ' Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial : Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC-an update from the PACIFIC trial ', Journal of Thoracic Oncology, vol. 16, no. 5, pp. 860-867 . https://doi.org/10.1016/j.jtho.2020.12.015
The New England Journal of Medicine, 378, 22, pp. 2078-2092 The New England journal of medicine, Vol. 378, no. 22, p. 2078-2092 (2018) The New England Journal of Medicine, 378, 2078-2092